Cardiac arrhythmia-detection startup BioSig Technologies (NSDQ:BSGM) has received nearly $1 million in financing from the Mayo Clinic after working with the healthcare organization for two years.
BioSig recently completed first-in-human studies at the Rochester, Minn.-based clinic aimed at validating the safety and efficacy of its Pure EP system during mapping and ablation procedures in a cardiac EP lab. Patient studies were also conducted at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center and at Greenville Memorial in North Carolina, according to the Wayzata, Minn.-based company. Previously, BioSig conducted preclinical studies at Mayo.
Get the full story on our sister site, Medical Design & Outsourcing.